Pairwise has licensed its Fulcrum® gene editing platform to the International Rice Research Institute (IRRI), a non-profit agricultural research organization. The agreement will enable IRRI to apply ...
Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by ...
A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes ...
CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeats, is a natural defense system in bacteria that scientists have adapted into a powerful gene-editing tool. This ...
Over the past two decades, synthetic biology has fueled advancements across a broad range of disciplines, including agriculture, bioremediation, biofuel production, and chemical manufacturing. Today, ...
In a world first, a bespoke gene-editing therapy benefitted one child. Now reseachers plan to launch a clinical trial of the ...
The U.S. government is divesting from mRNA vaccines, but will other uses of the technology be spared? In a time of ...
Health Secretary Robert F. Kennedy Jr. called the treatment 'a powerful glimpse into the future of personalized medicine' ...
A U.S. regulator reportedly plans to unveil a faster approach to approving custom gene-editing treatments for rare diseases. Vinay Prasad, who oversees gene therapies in the U.S. Food and Drug ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback